Hagens Berman and Robbins Geller publicized securities class-action claims over GeneDx's Fabric Genomics acquisition after first-quarter 2026 results included a roughly $31.2 million-$31.3 million impairment, weaker margins and reduced outlook.
GeneDx Holdings investors who bought shares between April 16, 2025 and May 4, 2026 face an August 3, 2026 deadline to seek appointment as lead plaintiff in securities class-action litigation alleging the company and certain executives misled investors about the Fabric Genomics acquisition and its expected benefits. The claims gained attention after GeneDx reported first-quarter 2026 results on May 4, 2026, including a roughly $31.2 million to $31.3 million impairment tied to Fabric Genomics, a sharp increase in net loss, a decline in adjusted gross margin to 69% from 74%, softer recurring-revenue trends, and reduced 2026 guidance; GeneDx shares fell more than 49% the next day, according to the complaints and law-firm releases.